VERU — VERU INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 863894 ·
Last close
$2.14
Market Cap
$36.49M
52W High
$7.33
52W Low
$2.03
ADV30
154,433
Next earnings
2026-12-17
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -7,713,681 | -6,988,350 | 37,027,670 | 23,880,142 | 8,651,430 |
| Mar 2026 | 0 | — | -7,218,968 | -2,741,132 | 43,082,726 | 27,596,820 | 8,297,105 |
| Dec 2025 | 0 | — | -5,424,015 | -5,332,579 | 47,567,030 | 32,991,417 | 10,442,989 |
| Sep 2025 | 0 | — | -7,459,363 | 1,453,507 | 29,835,719 | 15,794,562 | 11,503,049 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-26,042,991
Investing CF
$11,598,548
Financing CF
$23,314,431
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.18
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-332,357,975
Inventory
—
Receivables
—
ST Investments
$1,911,386
EBIT TTM
$-27,816,027
Pretax Income TTM
$-14,109,339
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Sep 2025 | 0 | -35,530,932 | -22,726,279 | 29,835,719 | 11,503,049 | 18,332,670 | -30,043,088 |
| Sep 2024 | 0 | -37,391,968 | -37,801,426 | 60,418,772 | 28,102,060 | 32,316,712 | -21,682,333 |
| Sep 2023 | 16,296,958 | -95,605,839 | -93,152,692 | 50,023,091 | 30,344,930 | 19,678,161 | -88,013,814 |
| Sep 2022 | 39,354,352 | -83,488,158 | -84,040,618 | 135,358,450 | 52,561,133 | 82,797,317 | -47,505,004 |
TTM Snapshot
Revenues TTM
$8,626,156
NetIncome TTM
$-13,608,554
OpCashFlow TTM
—
Assets (Latest)
$37,027,670
Forward EPS
$-0.98
Max Pain — expiry 2027-01-15
max pain strike: $3.00 · spot: $2.31 · call oi: 1,779 · put oi: 259
Expected Move to 2027-01-15:
±$0.95
(41.13%) —
implied range
$1.36 –
$3.26
· ATM straddle on $2.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CNTB | Connect Biopharma Holdings Ltd | $36.45M | $0.58 | — |
| SER | Serina Therapeutics, Inc. | $36.27M | $1.37 | — |
| GRCE | Grace Therapeutics, Inc. | $36.18M | $1.72 | — |
| BMEA | Biomea Fusion, Inc. | $35.47M | $0.49 | — |
| OSTX | OS Therapies Inc | $34.86M | $0.74 | — |
News headlines (Yahoo Finance, 1h cache)
Veru Presents New Results at ObesityWeek 2026: GLP-1 Weight Loss in Older Adults Associated with Physical Function Decline; Adding Enobosarm Preserved Significant Lean Mass and Physical Function
2026-11-17 13:30 · Yahoo
Veru to Present New Results on Effects of Enobosarm on Physical Function in Older Patients Receiving GLP-1 RA from the Phase 2b QUALITY clinical study at ObesityWeek 2026
2026-11-09 13:30 · Yahoo
Veru (VERU) Q3 2026 Earnings Call Transcript
2026-08-17 11:58 · Yahoo
Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss
2026-08-04 12:30 · Yahoo
Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference
2026-07-30 12:30 · Yahoo
Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
2026-07-27 12:10 · Yahoo
Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day
2026-07-07 12:30 · Yahoo
Veru And 2 Other Intriguing Penny Stocks To Watch
2026-06-05 12:05 · Yahoo
Earnings call transcript: Veru Inc Q2 2026 shows improved financials
2026-06-01 04:08 · Yahoo
Veru Teams Up With Novo Nordisk for Obesity Combination Therapy Trial (VERU)
2026-06-04 14:22 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.